

The State of Connecticut

January 1, 2025 Rx Drug Coverage Changes
for Dry Eye Disease and Acute Migraine




TruDataRx: A Differentiated Clinical Approach

TruDataRx approaches the challenge of navigating drug coverage policy decisions with a clinical lens first. Using our proprietary comparative effectiveness-based research and analytics, we objectively curate existing peer-reviewed data that measures and compares the clinical value of the medications within a condition, and use this information to facilitate our clients' drug coverage decision making processes.

The clinical effectiveness data is carefully identified from the highest quality, peer-reviewed data sources (i.e., meta-analyses and randomized controlled trials). Then, the data is curated and analyzed to determine the effectiveness of drugs in relation to each other along with the cost of each drug. The result looks similar to the illustrative example shown below.

Must ask "Compared to what?" Drug Mix driven by CER ensures formularies cover the most effective drugs at the best price



Promoting the highest quality drugs becomes easy with **Comparative Effectiveness Research (CER)**, which enables employers to compare drugs across classes and conditions on both a clinical and financial basis.

State of Connecticut: Rx Drug Coverage Changes for 2025

For more information or to request a copy of the Evidence Reviews supporting these changes, please contact us at OSC@trudatarx.com

ACUTE MIGRAINE

When will this happen?

- This change will go into effect on **1/1/2025** for new utilizers
- Current utilizers will be allowed to continue their drug, but will be encouraged to discuss the highly effective, \$0 options with their provider

What are the changes?

- Coverage for Nurtec, Ubrelvy, Reyvow, and sumatriptan nasal spray will require an inadequate response of two of the **most effective** triptans (eletriptan, rizatriptan, sumatriptan injection)
- Coverage for lowest value options (e.g. frovatriptan, almotriptan) will require members to demonstrate inadequate response to all covered options
- Rizatriptan and rizatriptan ODT will be moved to a **\$0 member copay tier** to align plan design with effectiveness and provide an additional member benefit as they transition to high value options

What do providers need to know?

- Providers will still follow the same process for Nurtec, Ubrelvy, Reyvow, and sumatriptan nasal coverage – however, the **criteria has changed**, and you will be asked to **submit medical records** that demonstrate the member has met the criteria

DRY EYE DISEASE

When will this happen?

- This change will go into effect on **1/1/2025** for new utilizers and **3/1/2025** for current utilizers

What are the changes?

- Coverage for Restasis, Cequa, Vevye, Tyrvaya, and Miebo will require an inadequate response to omega-3 fish oil and Xiidra
- Xiidra will remain covered with copay
- Omega-3 fish oil will be moved to a \$0 member copay tier to align plan design with effectiveness and provide an additional member benefit as they transition to the most effective option

What do providers need to know?

- **Medical necessity prior authorization** must be submitted for Restasis, Cequa, Vevye, Tyrvaya, and Miebo and you will be asked to **submit medical records** that demonstrate the member has met the criteria